[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"progressive-supranuclear-palsy-psp\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:progressive-supranuclear-palsy-psp":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,52,81,124,155,188],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100640300","early-molecular-biomarkers-for-differentiating-parkinsonian-syndromes-100640300",false,"NCT07604883","Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes","Identification of Molecular Biomarkers, Including microRNAs and Metabolites, Enabling Early Differentiation of Parkinson's Disease and Atypical Parkinsonian Syndromes in a Prospective Observational Study.","BIOMARK-PS","Inclusion Criteria:\n\nPatients with suspected neurodegenerative parkinsonism in the course of PD or APS, defined according to the 2015 MDS criteria as bradykinesia accompanied by at least one additional symptom: rigidity and\u002For resting tremor.\n\nAge between 40 and 80 years. Written informed consent for participation in the study. Duration of parkinsonian symptoms shorter than 3 years. Abnormal dopamine transporter single-photon emission computed tomography (DaTscan) result confirming presynaptic dopaminergic neuronal degeneration.\n\nExclusion Criteria Lack of consent to participate in the study. Secondary or drug-induced parkinsonism. Other central nervous system (CNS) disorders (e.g., neoplastic or vascular processes) that could account for the symptoms.\n\nActive malignancy, infection, or autoimmune inflammatory disease. Severe systemic diseases, including advanced heart failure (New York Heart Association \\[NYHA\\] class III-IV), poorly controlled diabetes mellitus, renal failure with glomerular filtration rate (GFR) ≤ 60 mL\u002Fmin\u002F1.73 m², or hepatic failure.\n\nPresence of a known monogenic mutation causing parkinsonism according to the Online Mendelian Inheritance in Man (OMIM) classification.\n\nAntibiotic therapy or use of probiotics within 3 months prior to the study visit.\n\nPregnancy or breastfeeding.",true,"ALL","40 Years","80 Years",{"count":22,"type":23},200,"ESTIMATED","OBSERVATIONAL","This prospective observational study aims to identify and preliminarily validate molecular biomarkers, including microRNAs and metabolites, for the early differentiation of Parkinson's disease (PD) from atypical parkinsonian syndromes (APS). The study will enroll up to 100 patients with PD, 50 patients with suspected APS, and 50 healthy controls.\n\nParticipants will undergo clinical assessments and provide blood, urine, and stool samples at baseline and after 12-18 months of follow-up. Molecular analyses, including microRNA profiling, metabolomics, RNA sequencing (RNA-seq), and microbiome analysis, will be performed to identify disease-specific diagnostic signatures.\n\nThe primary objective is to detect differences in molecular profiles among patients with PD, patients with APS, and healthy controls. Secondary objectives include evaluating the diagnostic accuracy of biomarker panels and assessing longitudinal changes in these biomarkers over time.\n\nAlthough participants will not receive direct therapeutic benefits, the study may contribute to the development of non-invasive tools for the early diagnosis and improved differentiation of parkinsonian disorders.",[27,28,29,30,31],"PARKINSON DISEASE (Disorder)","Atypical Parkinsonism","Multiple System Atrophy","Progressive Supranuclear Palsy (PSP)","Dementia With Lewy Bodies (DLB)",[33,34,35,36,37,38],"parkinson disease","atypical parkinsonism","progressive supranuclear palsy","multiple system atrophy","dementia with lewy bodies","biomarker","NOT_YET_RECRUITING","2026-05-25",{"date":42,"type":43},"2026-05-28","ACTUAL",{"date":45,"type":23},"2026-06-04",{"date":47,"type":23},"2029-06-04",{"name":49,"class":50},"International Institute of Molecular and Cell Biology in Warsaw","OTHER_GOV",2,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":18,"minAge":59,"maxAge":20,"enrollmentInfo":60,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100448558","synaptic-loss-in-multiple-system-atrophy-100448558","NCT05121012","Synaptic Loss in Multiple System Atrophy","Molecular Imaging of Synaptic Loss in Multiple System Atrophy (MSA)","Inclusion Criteria\n\nMSA group:\n\nMale or female, aged 45-80 at the time of informed consent. Meet criteria for diagnosis of probable or possible MSA (Gilman et al., 2008) (Appendix 1).\n\nA female subject is eligible to participate if she is a) of non-childbearing potential, defined as pre-menopausal females with a documented tubal ligation or hysterectomy, or postmenopausal defined as 12 months of spontaneous amenorrhea or b) of childbearing potential but not pregnant (as determined by urinary pregnancy test on screening and on each study day), is not lactating and is willing to use one of the contraception methods listed below:\n\n* Combined (estrogen and progesterone containing) hormonal contraception associated with initiation of ovulation( oral, intravaginal, or transdermal);\n* Progesterone-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable);\n* Intrauterine device;\n* Intrauterine hormone releasing system;\n* Bilateral tubal occlusion;\n* Vasectomized partner;\n* Sexual abstinence.\n\nMale subject with a female partner of child-bearing potential must use one of the following contraceptive methods for 90 days after each dose of radiotracer:\n\n* Condom plus partner use of a highly effective contraceptive (see point above) OR\n* Abstinence Subjects must understand the nature of the study and be able to provide signed and dated written informed consent in accordance with local regulations before the conduct of any study-related procedures. They must be able and willing to participate in all scheduled evaluations, abide by all study restrictions, and complete all required tests and procedures.\n\nMust have anticipated survival of ≥3 years (in the opinion of the Investigator).\n\nMedical treatment of MSA and co-morbid medical conditions must be stable for at least 30 days prior to screening and between screening and baseline PET scan. Intermittently administered treatment may be considered stable if the dose and dosing frequency have been unchanged for the greater of 30 days or three dosing inbiomartervals (e.g. a treatment given once a month must be at a stable dose and dosing frequency for 3 months).\n\nFor inclusion in optional CSF sampling, written informed consent must be provided, either by separate signed and dated written informed consent or by specific written acknowledgement on the main study informed consent form, according to local procedure. Failure to participate in optional CSF sampling will have no influence on the subject's ability to participate in the main study.\n\nIn the opinion of the investigator, the subject must be considered likely to comply with the study protocol and to have high probability of completing the study.\n\nPSP Group:\n\nMale or female, aged 45-80 at the time of informed consent. Meet criteria for diagnosis of suggestive, probable or possible PSP - with preference for PSP-RS, PSP-OM, PSP-PI, PSP with gait freezing, and PSP-SL and PSP-P subtypes (Höglinger et al., 2017 (Appendix 2).\n\nA female subject is eligible to participate if she is a) of non-childbearing potential, defined as pre-menopausal females with a documented tubal ligation or hysterectomy, or postmenopausal defined as 12 months of spontaneous amenorrhea or b) of childbearing potential but not pregnant (as determined by urinary pregnancy test on screening and on each study day), is not lactating and is willing to use one of the contraception methods listed below:\n\n* Combined (estrogen and progesterone containing) hormonal contraception associated with initiation of ovulation( oral, intravaginal, or transdermal);\n* Progesterone-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable);\n* Intrauterine device;\n* Intrauterine hormone releasing system;\n* Bilateral tubal occlusion;\n* Vasectomized partner; Sexual abstinence.\n\nMale subject with a female partner of child-bearing potential must use one of the following contraceptive methods for 90 days after each dose of radiotracer:\n\n• Condom plus partner use of a highly effective contraceptive (see point above) OR Abstinence Subjects must understand the nature of the study and be able to provide signed and dated written informed consent in accordance with local regulations before the conduct of any study-related procedures. They must be able and willing to participate in all scheduled evaluations, abide by all study restrictions, and complete all required tests and procedures.\n\nExclusion criteria:\n\nMSA group:\n\nHistory of other neurological disorders or intracranial co-morbidities, such as stroke, haemorrhage, space-occupying lesions.\n\nPresence of supranuclear gaze palsy. Presence of any clinically significant medical condition (including cardiovascular, respiratory, cerebrovascular, hematological, hepatic, renal, gastrointestinal, or other disease) that, based on the judgement of the investigator, is clinically unstable, is likely to deteriorate during the course of the study, could put the patient at risk because of participation in the study, could affect the subject's ability to complete the study, or could influence the study results.\n\nSevere-to-complete dependence on caregivers (score \\>3 on UMSARS Part IV, Global Disability), severe impairment of swallowing (score ≥3 on UMSARS Part I, Question 2), or frequent falls (score ≥3 on UMSARS Part I, Question 8) at Screening.\n\nPresence of any of the following MRI contraindications: pacemaker; cardiac defibrillator; spinal cord or vagus nerve stimulator; aneurysm clip; artificial heart valve; recent coronary or carotid stent; ear implant; CSF shunt; other implanted medical device (e.g. Swan-Ganz catheter, insulin pump); or metal fragments or foreign objects in the eyes, skin, or body. If the principal investigator considers the presence of any of the above not to be a contraindication to MRI in a given subject, the investigator may obtain approval from the MR operators based on a discussion of the case.Negative modified Allen test in both hands.\n\nHistory of claustrophobia or back pain that makes prolonged laying on the MRI or PET scanner intolerable.\n\nPregnancy, lactation, or, if female of childbearing potential, positive urine β-hCG at screening or prior to PET scan.\n\nUse of drugs acting on SV2A such as antiepileptics (e.g. levetiracetam or brivaracetam).\n\nHistory of brain surgery for parkinsonism or stem cell treatment. Clinically significant blood clotting or bleeding disorder, including clinically significant abnormal findings in laboratory assessments of coagulation or hematology.\n\nCurrent or recent history of alcohol or drug abuse \u002F dependence (except nicotine dependence).\n\nHistory of cancer within the last 5 years, with the exception of nonmetastatic basal cell carcinoma of the skin.\n\nHemoglobin A1c (HbA1c) ≥ 6.5% at screening. Uncontrolled\u002Fpoorly controlled diabetes mellitus.\n\nFor subjects participating in optional CSF sampling:\n\n* Any spinal malformation or other aspects (e.g. tattoos) \u002F clinical findings (e.g. papilledema) that may complicate or contraindicate lumbar puncture, as judged by the investigator.\n* Neoplasm or other space-occupying intracranial lesion on MRI. Any clinically important abnormality, as determined by the investigator, on physical examination or vital signs, ECG, or clinical laboratory test results other than abnormality due to a stable, well-controlled medical condition; or any abnormality that could be detrimental to the subject or could compromise the study.\n\nPSP group:\n\nHistory of other neurological disorders or intracranial co-morbidities, such as stroke, haemorrhage, space-occupying lesions.\n\nInclusion in any clinical trial with investigational drugs targeting tau. Presence of any clinically significant medical condition (including cardiovascular, respiratory, cerebrovascular, hematological, hepatic, renal, gastrointestinal, or other disease) that, based on the judgement of the investigator, is clinically unstable, is likely to deteriorate during the course of the study, could put the patient at risk because of participation in the study, could affect the subject's ability to complete the study, or could influence the study results.\n\nPresence of any of the following MRI contraindications: pacemaker; cardiac defibrillator; spinal cord or vagus nerve stimulator; aneurysm clip; artificial heart valve; recent coronary or carotid stent; ear implant; CSF shunt; other implanted medical device (e.g. Swan-Ganz catheter, insulin pump); or metal fragments or foreign objects in the eyes, skin, or body. If the principal investigator considers the presence of any of the above not to be a contraindication to MRI in a given subject, the investigator may obtain approval from the MR operators based on a discussion of the case.\n\nAbnormal modified Allen test in both hands. History of claustrophobia or back pain that makes prolonged laying on the MRI or PET scanner intolerable.\n\nPregnancy, lactation, or, if female of childbearing potential, positive urine β-hCG at screening or prior to PET scan.\n\nHistory of brain surgery for parkinsonism or stem cell treatment. Clinically significant blood clotting or bleeding disorder, including clinically significant abnormal findings in laboratory assessments of coagulation or hematology.\n\nCurrent or recent history of alcohol or drug abuse \u002F dependence (except nicotine dependence).\n\nHistory of cancer within the last 5 years, with the exception of nonmetastatic basal cell carcinoma of the skin.\n\nFor subjects participating in optional CSF sampling:\n\n• Any spinal malformation or other aspects (e.g. tattoos) \u002F clinical findings (e.g. papilledema) that may complicate or contraindicate lumbar puncture, as judged by the investigator.\n\nNeoplasm or other space-occupying intracranial lesion on MRI. Any clinically important abnormality, as determined by the investigator, on physical examination or vital signs, ECG, or clinical laboratory test results other than abnormality due to a stable, well-controlled medical condition; or any abnormality that could be detrimental to the subject or could compromise the study.","45 Years",{"count":61,"type":23},36,"In this study the investigators would like to investigate the degree of damage of the synapses, an important part of the neurons vital for the communications between neurons, in Multiple System Atrophy (MSA), and pathology related to abnormal accumulation of a protein named tau, in Progressive Supranuclear Palsy (PSP).",[29,30],[65,66,29,67,68],"Neurodegeneration","Positron Emission Tomography","Biomarkers","Progressive Supranuclear Palsy","RECRUITING","2026-02-06",{"date":72,"type":43},"2026-02-10",{"date":74,"type":43},"2021-09-01",{"date":76,"type":23},"2027-03-31",{"name":78,"class":79},"University of Exeter","OTHER",1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":17,"sex":18,"minAge":87,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":90,"conditions":91,"keywords":109,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":80},"100565858","the-curepsp-genetics-program-100565858","NCT06647641","The CurePSP Genetics Program","Inclusion Criteria:\n\n1. Adults (aged 35 or older) with a clinical diagnosis of PSP, CBS, MSA, or a related neurological disease as confirmed by their healthcare provider, or unaffected family members of participants who have reported a family history of relevant neurodegenerative conditions.\n2. Meet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Possible or Probable PSP (32), clinically established or clinically probable MSA (33), Armstrong criteria (2013) for possible or probable CBS (34). Diagnostic certainty will be determined by the treating\u002Freferring clinician.\n3. Willingness to undergo genetic testing. Participants will have the option to receive relevant genetic test results.\n4. Have the capacity to give full informed consent in writing or electronically, or provide consent through a legally authorized representative (LAR)\u002Fpower of attorney (POA), and have read, understood, and completed the informed consent form.\n5. Are able to perform or have a designee who can perform study activities (including completion of either online or orally administered surveys).\n\nExclusion Criteria:\n\n1. Individuals who have received a blood transfusion within the past 3 months.\n2. Individuals who have active hematologic malignancies such as lymphoma or leukemia.\n3. Individuals who have had a bone marrow transplant within the past 5 years.\n4. Individuals under the age of 35 or age of majority in applicable states at the time of consenting.","35 Years",{"count":89,"type":23},1000,"This study is an observational, prospective genetic study. It aims to obtain DNA for research and testing from patients with PSP, CBS, MSA, and related neurological conditions and their families.\n\nUp to 1,000 adults who have been clinically diagnosed with PSP, CBS, MSA, or related neurological conditions will be enrolled. The study intervention involves sequencing of participant blood samples using non-CLIA-approved whole genome sequencing at the National Institutes of Health. Pathogenic variants that are deemed possibly related to these conditions will be confirmed using CLIA-approved testing. The study involves minimal risk to participants.",[92,93,94,95,96,97,98,99,100,101,102,29,103,104,105,106,107,68,108,30],"PSP","PSP - Progressive Supranuclear Palsy","Corticobasal Syndrome","Corticobasal Syndrome(CBS)","Corticobasal Degeneration Syndrome","Corticobasal Degeneration","Corticobasal Degeneration (CBD)","Corticobasal Syndrome (CBS)","MSA","MSA - Multiple System Atrophy","MSA-C","Multiple System Atrophy (MSA) With Orthostatic Hypotension","Multiple System Atrophy - Cerebellar Subtype (MSA-C)","Multiple System Atrophy - Parkinsonian Subtype (MSA-P)","Multiple System Atrophy, Cerebellar Type","Multiple System Atrophy, Parkinsonian Type","Progressive Supranuclear Palsy(PSP)",[110,68,29,111,112,92,100,113,114],"genetic study","Corticobasal","CurePSP","CBD","Genes","2026-01-12",{"date":117,"type":43},"2026-01-14",{"date":119,"type":43},"2024-10-08",{"date":121,"type":23},"2030-12-31",{"name":123,"class":79},"Massachusetts General Hospital",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":17,"sex":18,"minAge":131,"maxAge":20,"enrollmentInfo":132,"targetDuration":4,"studyType":134,"phases":135,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":80},"100619719","early-phase-1-first-in-human-study-for-the-safety-and-evaluation-of-two-4r-tau-ligands-as-potential-pet-radioligands-for-imaging-tau-protein-in-the-brain-100619719","NCT07348276","First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain","First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands ([18F]ABBV964i and [ 18F]ABBV-965i) as Potential PET Radioligands for Imaging Tau Protein in the Brain of Patients With Probable PSP and Healthy Volunteers","Inclusion Criteria:\n\n* Males or females: PSP 40-80 years; HV 18-80 years\n* Body weight: 43-120 kg (95-265 lb)\n* Women of childbearing potential: abstinent or use 2 contraception methods (one barrier) during study and 30 days post last injection\n* Men: use 2 contraception methods and refrain from sperm donation during study and 90 days post last injection\n* Adequate circulation and normal clotting for arterial cannulation\n* Sufficient mobility and ability to lie still for imaging\n* Healthy Volunteers: informed consent, no clinically relevant findings, no cognitive impairment\n* PSP Participants: informed consent or assent with LAR consent, clinical diagnosis per NINDS-SPSP criteria, MRI consistent with PSP, able to ambulate, tolerate MRI, comply with study procedures, caregiver available if needed\n\nExclusion Criteria:\n\n* History of drug or alcohol abuse in past 12 months\n* Clinically significant lab abnormalities or unstable illness\n* Investigational drug\u002Fdevice use within 30 days\n* Pregnant, lactating, or breastfeeding\n* Significant comorbid conditions (GI, CV, hepatic, renal, etc.)\n* Abnormal clotting parameters (if arterial sampling)\n* MRI contraindications (implants, claustrophobia) for PSP participants\n* Use of OTC meds or supplements within 2 weeks (healthy volunteers)\n* Use of anti-hemostasis meds within 2 weeks of arterial line placement for PSP participants\n* Unable to lie still for 90 minutes\n* Major surgery or significant blood loss within 4 weeks\n* Positive for Hepatitis B, Hepatitis C, or HIV\n* Deemed unsuitable by Investigator","18 Years",{"count":133,"type":23},24,"INTERVENTIONAL",[136],"EARLY_PHASE1","This clinical study is being conducted to learn more about two new imaging drugs, called \\[18F\\]ABBV-964i and \\[18F\\]ABBV-965i, which are designed to help doctors see changes in the brain related to a condition called Progressive Supranuclear Palsy (PSP). PSP is a rare disease that affects movement, balance, and thinking. These drugs are used with a type of scan called PET (Positron Emission Tomography) to show areas of the brain where a protein called tau builds up. Tau buildup is linked to PSP and other brain diseases.\n\nThe main goal of this study is to find out if these imaging drugs are safe for people and if they work well to show tau in the brain. The study will also look at how the drugs move through the body and how much radiation they give off. Researchers hope this information will help develop better tools for diagnosing PSP and tracking how it changes over time.\n\nWho can join? Adults who are healthy or who have PSP may be able to take part. Participants will have screening tests to make sure they qualify.\n\nWhat does participation involve? People in the study will have PET scans, blood tests, and other safety checks. Some participants will also have an MRI scan. The study is divided into three parts: Part A checks radiation levels in healthy volunteers, Part B looks at how the drugs work in the brain of PSP patients and healthy volunteers, and Part C (optional) repeats scans to see if results are consistent.\n\nWhy is this important? There is currently no cure for PSP, and better imaging tools could help researchers develop new treatments. By joining this study, participants will help advance research that may improve care for people with PSP and similar conditions in the future.",[30,139],"Healthy Participants",[141,142,143,144,145,92,68],"Tauopathy","Tau","PET Imaging","ABBV-965i","ABBV-964i","2026-01-09",{"date":148,"type":43},"2026-01-16",{"date":150,"type":43},"2025-11-17",{"date":152,"type":23},"2027-03",{"name":154,"class":79},"Invicro",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":18,"minAge":131,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":134,"phases":164,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":80},"100603463","gait-analysis-parameter-and-upper-limb-evaluation-in-adult-patients-with-neurological-or-metabolic-pathology-100603463","NCT07136844","Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology","Acti-Adult","Inclusion Criteria:\n\n* Ambulant patients (i.e. able to walk 10 meters without assistance)\n* Confirmed diagnosis by the investigator based on current gold standard in his\u002Fher disease (genetic testing, clinical criteria, etc.)\n\n  * Myotonic dystrophy type 1 (DM1) and Charcot-Marie-Tooth (CMT) patients should present sensitive of motor signs on physical examination.\n  * Myasthenic patients should be seropositive, and Myasthenia Gravis Foundation of America (MGFA) class II to IV.\n  * Patient with morbid obesity (Body Mass Index\\> or = 35 at inclusion visit).\n* Signed informed consent form by patient him\u002Fherself and patient willing and able to comply with all study procedures.\n\nExclusion Criteria:\n\n* Non-ambulant patients\n* Patients with extreme cognitive disorders that limit their understanding of the exercises to be performed\n* Patients who have undergone a surgical procedure or who have experienced recent trauma (within fewer than 6 months) affecting the upper or lower limbs\n* A concomitant chronic or acute neurological, endocrine, infectious, allergic, or inflammatory pathology within the 3-week period immediately prior to inclusion\n* Patients who are participating in an interventional clinical trial\n* Pregnant or breastfeeding women",{"count":163,"type":23},300,[165],"NA","The ActiLiège-Adult study is a prospective, longitudinal, observational study designed to collect natural history data on adult patients with neurological or metabolic diseases affecting movement. Conducted at the Centre de Référence Liégeois des Maladies Neuromusculaires in Liège, Belgium, the study will enroll 300 ambulant patients, including individuals with neuromuscular disorders and obesity. Using the Syde® wearable device, the study aims to continuously monitor motor function in real-life settings over a period of up to two years. The primary objective is to evaluate the utility of digital mobility outcomes, such as the 95th centile of stride velocity (SV95C), as reliable and objective endpoints for future clinical trials.",[168,169,170,171,172,173,174,175,176,30,177,178],"Neuromuscular Diseases","Obesity (Disorder)","Myotonic Dystrophy 1","Myasthenic Syndrome","Charcot Marie Tooth Disease (CMT)","Glycogen Storage Disease Type II Pompe Disease","Facio-Scapulo-Humeral Dystrophy","Myasthenia Gravis","Huntington Disease","Hereditary Spastic Paraplegia","Ataxia, Spinocerebellar","2025-08-14",{"date":181,"type":43},"2025-08-22",{"date":183,"type":43},"2024-03-29",{"date":185,"type":23},"2030-12",{"name":187,"class":79},"Centre Hospitalier Universitaire de Liege",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":17,"sex":18,"minAge":131,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":219},"100390419","artfl-lefftds-longitudinal-frontotemporal-lobar-degeneration-allftd-100390419","NCT04363684","ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)","Longitudinal Arm Inclusion Criteria\n\nFamilial FTLD (f-FTLD) participants (either is acceptable):\n\n* members of families in whom at least one member has a known disease-associated mutation in one of the major genes that cause f-FTLD: MAPT, GRN, C9orf72 (or other rare genes)\n* an autosomal dominant family history of a FTLD syndrome (without a known gene) verified by medical record review or well-documented family history including family members with a medical history consistent with FTLD or a related disorder.\n\nSporadic FTLD (s-FTLD) participants:\n\nSporadic participants should be symptomatic with no known family history nor a genetic mutation indicating f-FTLD. All sporadic participants must have an FTLD syndrome as a referring diagnosis; those determined by ALLFTD clinicians to have non-FTLD diagnoses will be excluded from longitudinal visits, but their baseline visit will be included in comparative datasets. For inclusion in the longitudinal follow-up, participants should meet research criteria for one of the following FTLD syndromes:\n\n* Progressive Supranuclear Palsy (PSP)\n* Semantic variant Primary Progressive Aphasia (svPPA)\n* Nonfluent variant Primary Progressive Aphasia (nfvPPA)\n* Corticobasal Degeneration (CBD)\u002FCorticobasal Syndrome (CBS)\n* Behavioral variant Frontotemporal dementia (bvFTD)\n* Frontotemporal Dementia with Amyotrophic Lateral Sclerosis (FTD\u002FALS)\n\nBiofluid-Focused Arm Inclusion Criteria\n\nParticipants enrolled in the biofluid arm may be either f-FTLD or s-FTLD. All general inclusion criteria apply. Participants should meet research criteria (as specified above) for any FTLD syndrome or meet familial FTLD inclusion criteria. Because the biofluid arm participants do not undergo the same detailed clinical and functional assessments required for the longitudinal arm, participants may be included regardless of primary language, as long as an appropriately translated consent is available.\n\nExclusion Criteria:\n\n* Known presence of a structural brain lesion (e.g. tumor, cortical infarct) that could reasonably explain symptoms in a symptomatic participant.\n* Known presence of an Alzheimer's disease causing mutation in PSEN1, PSEN2 or APP; or biomarker evidence for Alzheimer's disease as a cause of the clinical syndrome.\n* A previous history of Korsakoff encephalopathy, severe alcohol dependence (within 5 years of onset of dementia), frequent alcohol or other substance intoxication, or other neurological disorder.\n* Evidence through history or laboratory testing of uncorrected B12 deficiency (B12 \\\u003C 95% of local laboratory's normal value), unregulated hypothyroidism (TSH \\>150% of normal), HIV positive, renal failure (creatinine \\> 2), liver failure (ALT or AST \\> two times normal), respiratory failure that requires supplemental oxygen, large confluent white matter lesions, significant systemic medical illnesses such as deteriorating cardiovascular disease.\n* Current medication likely to affect CNS functions in the opinion of the site PI.\n* In the site investigator's opinion, the participant cannot complete sufficient key study procedures. The participant may be enrolled into the biofluid-focused arm if they can tolerate a blood draw and short clinical exam, but must be able to complete at least 75% of study procedures for enrollment into the longitudinal arm.",{"count":195,"type":23},2100,"ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.",[198,30,98,199,200,201,202,203,204,205,206,207,208,209],"Frontotemporal Lobar Degeneration (FTLD)","Behavioral Variant Frontotemporal Dementia (bvFTD)","Semantic Variant Primary Progressive Aphasia (svPPA)","Nonfluent Variant Primary Progressive Aphasia (nfvPPA)","FTD With Amyotrophic Lateral Sclerosis (FTD\u002FALS)","Amyotrophic Lateral Sclerosis","Oligosymptomatic PSP (oPSP)","C9orf72","GRN Related Frontotemporal Dementia","MAPT Gene Mutation","TBK1 Gene Mutation","Oligosymptomatic Progressive Supranuclear Palsy","2025-07-08",{"date":212,"type":43},"2025-07-11",{"date":214,"type":43},"2020-03-01",{"date":216,"type":23},"2026-06-30",{"name":218,"class":79},"Mayo Clinic",27]